Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases with significant unmet medical needs. Headquartered in Cardiff, United Kingdom, and publicly listed on NASDAQ (BDRX), the company operates within the biotechnology sector. Biodexas core strategy centers on building a pip... eline of novel drug candidates targeting serious and often rare conditions, including oncology and metabolic diseases. Its lead program, eRapa, is an oral formulation of rapamycin designed to treat familial adenomatous polyposis (FAP), a rare disorder that can lead to colorectal cancer if untreated. In addition to eRapa, the company is developing other key therapies such as Tolimidone for type 1 diabetes and MTX110, a treatment aimed at aggressive brain cancers like glioblastoma and diffuse midline glioma. Biodexa also leverages proprietary drug delivery technologies to improve the effectiveness and bioavailability of its treatmentsRead More